ISRG Stock Analysis: Intuitive Surgical | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 118.955m USD | 12M Return: -30.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.31B
EPS Trend: 99.8%
Qual. Beats: 5
Rev. Trend: 99.8%
Qual. Beats: 8
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Intuitive Surgical, Inc. (NASDAQ: ISRG) develops and markets technologies that enable minimally invasive care, anchored by its flagship da Vinci Surgical System, a robotic-assisted platform used in surgical procedures. The company has extended its portfolio with the Ion endoluminal system, which supports minimally invasive lung biopsies, moving beyond the operating room into diagnostic procedures.
The business model combines capital equipment sales of surgical systems with a recurring revenue stream from disposable instruments, energy devices, and stapling products used in each procedure, supplemented by installation, maintenance, 24/7 technical support, and digital program-management services. Products are sold through direct capital and clinical sales teams, and the company maintains a deep customer-service and training infrastructure. As a medical-device manufacturer, ISRG operates in a sector characterized by long product cycles, significant regulatory oversight, and high switching costs once a hospital system is integrated into a platform.
Intuitive Surgical was incorporated in 1995, is headquartered in Sunnyvale, California, and trades as a large-cap stock in the Health Care Equipment sub-industry, having gone public in 2000.
- Da Vinci procedure volume drives recurring instrument and accessory revenue
- Ion endoluminal system adoption accelerates diagnostic lung biopsy growth
- Medtronic Hugo and J&J Ottava intensify robotic surgery competition
- Hospital capital budget cycles pressure new system placements
| Net Income: 3.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 5.55 > 1.0 |
| NWC/Revenue: 69.05% < 20% (prev 77.13%; Δ -8.07% < -1%) |
| CFO/TA 0.18 > 3% & CFO 3.71b > Net Income 3.14b |
| Net Debt (-4.83b) to EBITDA (4.51b): -1.07 < 3 |
| Current Ratio: 4.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (358.5m) vs 12m ago -1.54% < -2% |
| Gross Margin: 66.68% > 18% (prev 66.61%; Δ 0.07% > 0.5%) |
| Asset Turnover: 53.77% > 50% (prev 45.35%; Δ 8.42% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.36 (Total Current Assets 9.54b - Total Current Liabilities 1.92b) / Total Assets 20.9b |
| B: 0.33 (Retained Earnings 6.84b / Total Assets 20.9b) |
| C: 0.18 (EBIT TTM 3.73b / Avg Total Assets 20.5b) |
| D: 7.05 (Book Value of Equity 18.2b / Total Liabilities 2.58b) |
| Altman-Z'' = 12.08 = AAA |
| DSRI: 0.99 (Receivables 1.67b/1.39b, Revenue 11.0b/9.14b) |
| GMI: 1.00 (GM 66.61% / 66.68%) |
| AQI: 0.87 (AQ_t 0.28 / AQ_t-1 0.32) |
| SGI: 1.21 (Revenue 11.0b / 9.14b) |
| TATA: -0.03 (NI 3.14b - CFO 3.71b) / TA 20.9b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of July 26, 2026, the stock is trading at USD 337.50 with a total of 3,436,653 shares traded. Over the past week, the price has changed by -2.29%, over one month by -16.01%, over three months by -30.01% and over the past year by -30.93%.
Current recommended Stop Loss: 317.50 (which is 5.9% or 1.2 ATR below the current price).
Intuitive Surgical has received a consensus analysts rating of 4.03. Therefore, it is recommended to buy ISRG.
- StrongBuy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 490.5 | 45.3% |
P/E Trailing = 39.0612
P/E Forward = 32.7869
P/S = 10.7804
P/B = 6.6709
P/EG = 1.7349
Revenue TTM = 11.0b USD
EBIT TTM = 3.73b USD
EBITDA TTM = 4.51b USD
Long Term Debt = unknown (none)
Short Term Debt = 39.0m USD (from shortTermDebt, last fiscal year)
Debt = 389.8m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 87.0m
Net Debt = -4.83b USD (calculated: Debt 389.8m - CCE 5.22b)
Enterprise Value = 114b USD (119b + Debt 389.8m - CCE 5.22b)
Interest Coverage Ratio = unknown (Ebit TTM 3.73b / Interest Expense TTM 0.0)
EV/FCF = 35.42x (Enterprise Value 114b / FCF TTM 3.22b)
FCF Yield = 2.82% (FCF TTM 3.22b / Enterprise Value 114b)
FCF Margin = 29.21% (FCF TTM 3.22b / Revenue TTM 11.0b)
Net Margin = 28.45% (Net Income TTM 3.14b / Revenue TTM 11.0b)
Gross Margin = 66.68% ((Revenue TTM 11.0b - Cost of Revenue TTM 3.68b) / Revenue TTM)
Gross Margin QoQ = 67.78% (prev 66.06%)
Tobins Q-Ratio = 5.47 (Enterprise Value 114b / Total Assets 20.9b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 389.8m)
Taxrate = 17.02% (647.9m / 3.81b)
NOPAT = 3.09b (EBIT 3.73b * (1 - 17.02%))
Current Ratio = 4.96 (Total Current Assets 9.54b / Total Current Liabilities 1.92b)
Debt / Equity = 0.02 (Debt 389.8m / totalStockholderEquity, last quarter 18.2b)
Debt / EBITDA = -1.07 (Net Debt -4.83b / EBITDA 4.51b)
Debt / FCF = -1.50 (Net Debt -4.83b / FCF TTM 3.22b)
Total Stockholder Equity = 17.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.30% (Net Income 3.14b / Total Assets 20.9b)
RoE = 17.83% (Net Income TTM 3.14b / Total Stockholder Equity 17.6b)
RoCE = 19.66% (EBIT 3.73b / Capital Employed (Total Assets 20.9b - Current Liab 1.92b))
RoIC = 16.76% (NOPAT 3.09b / Invested Capital 18.4b)
WACC = 8.90% (E(119b)/V(119b) * Re(8.93%) + D(389.8m)/V(119b) * Rd(0.0%) * (1-Tc(0.17)))
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -40.19 | Cagr: -0.25%
[DCF] Terminal Value 76.21% ; FCFF base≈2.73b ; Y1≈3.13b ; Y5≈4.61b
[DCF] Fair Price = 189.9 (EV 63.2b - Net Debt -4.83b = Equity 68.0b / Shares 358.3m; r=8.90% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.79 | EPS CAGR: 25.59% | SUE: 2.97 | # QB: 5
Revenue Correlation: 99.75 | Revenue CAGR: 19.47% | SUE: 1.36 | # QB: 8
EPS current Quarter (2026-09-30): EPS=2.63 | Chg30d=+1.74% | Revisions=+40% | Analysts=24
EPS current Year (2026-12-31): EPS=10.79 | Chg30d=+3.57% | Revisions=+40% | GrowthEPS=+20.8% | GrowthRev=+17.0%
EPS next Year (2027-12-31): EPS=12.02 | Chg30d=+1.98% | Revisions=-40% | GrowthEPS=+11.4% | GrowthRev=+12.5%
[Analyst] Revisions Ratio: +22% (up=4, down=2)